Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 12/20 | 0.72 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | DRD2 | P14416 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.62 |
| ▸ | DRD3 | P35462 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.62 |
| ▸ | DRD1 | P21728 | 4/20 | 0.62 |
| ▸ | MTOR | P42345 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexoprenaline SCHEMBL32668781 | 1.00 | ADRB2 (0.72) | ADRB2MAPTADRB1TDP1KDM4E | |
| Hexoprenaline SCHEMBL3500862 | 0.98 | ADRB2 (0.70) | ADRB2MAPTADRB1TDP1KDM4E | |
| Hexoprenaline SCHEMBL1604446 | 0.98 | ADRB2 (0.70) | ADRB2MAPTADRB1TDP1KDM4E | |
| Hexoprenaline SCHEMBL598186 | 0.94 | ADRB2 (0.65) | ADRB2MAPTADRB1TDP1KDM4E | |
| SCHEMBL8442887 | 0.92 | ADRB2 (0.63) | ADRB2MAPTADRB1TDP1KDM4E | |
| SCHEMBL9768151 | 0.92 | ADRB2 (0.63) | ADRB2MAPTADRB1TDP1KDM4E | |
| SCHEMBL9768158 | 0.92 | ADRB2 (0.63) | ADRB2MAPTADRB1TDP1KDM4E | |
| SCHEMBL31530706 | 0.91 | ADRB2 (0.68) | ADRB2MAPTADRB1TDP1KDM4E | |
| SCHEMBL31530707 | 0.91 | ADRB2 (0.68) | ADRB2MAPTADRB1TDP1KDM4E | |
| SCHEMBL13790391 | 0.91 | ADRB2 (0.62) | ADRB2MAPTADRB1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4190 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250057764-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | ASTRAZENECA AB (SE) | 2025-02-20 | — | — | US | claimed |
| EP-3711797-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2025-02-12 | — | — | EP | claimed |
| WO-2025021913-A1 | SMALL MOLECULE PROSTAGLANDIN F RECEPTOR ANTAGONISTS | FERRING B.V. (NL) | 2025-01-30 | — | — | WO | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| EP-4452230-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | Astrazeneca AB (SE) | 2024-10-30 | — | — | EP | claimed |
| US-5215751-A | THERAPEUTIC SYSTEM FOR THE RETARDED AND CONTROLLED TRANSDERMAL OR TRANSMUCOUS ADMINISTRATION OF ACTIVE SUBSTANCES (I) | LTS LOHMANN THERAPIE SYSTEME GMBH & CO. (DE) | 1993-06-01 | — | — | US | claimed |
| EP-0384267-B1 | THERAPEUTIC SYSTEM FOR THE SUSTAINED AND CONTROLLED TRANSDERMAL OR TRANSMUCOSAL DELIVERY OF ACTIVE AGENTS | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1993-05-26 | — | — | EP | claimed |
| EP-0298984-A1 | COMPOSITIONS OF LIPOSOMES AND $g(b) 2?-RECEPTOR ACTIVE SUBSTANCES | Aktiebolaget Draco (SE) | 1989-01-18 | — | — | EP | claimed |
| EP-0282537-A1 | A NEW SYSTEM FOR ADMINISTRATION OF LIPOSOMES TO MAMMALS | Aktiebolaget Draco (SE) | 1988-09-21 | — | — | EP | claimed |
| WO-1988001862-A1 | A NEW SYSTEM FOR ADMINISTRATION OF LIPOSOMES TO MAMMALS | AKTIEBOLAGET DRACO (SE) | 1988-03-24 | — | — | WO | claimed |
| EP-0260241-A1 | A new system for administration of liposomes to mammals | Aktiebolaget Draco (SE) | 1988-03-16 | — | — | EP | claimed |
| WO-1987005803-A1 | COMPOSITIONS OF LIPOSOMES AND beta2-RECEPTOR ACTIVE SUBSTANCES | AKTIEBOLAGET DRACO (SE) | 1987-10-08 | — | — | WO | claimed |
| EP-0022932-B1 | COMPOSITION WITH PROLONGED BRONCHOLYTIC AND TOKOLYTIC ACTIVITY, PROCESS FOR PREPARING IT, AND BRONCHOLYTICALLY AND TOKOLYTICALLY ACTIVE AGENT | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1983-11-02 | — | — | EP | claimed |
| US-4380534-A | WAXES, STEROIDS, ALKALOIDS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1983-04-19 | — | — | US | claimed |
| US-4344933-A | HEXOPRENALINE COMPOUND WITH A CROSSLINKED STYRENE POLYMER | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1982-08-17 | — | — | US | claimed |